Positive Clinical Trials and FDA Advancements Bolster Buy Rating for PTC Therapeutics
Robert W. Baird analyst Joel Beatty has maintained their bullish stance on PTCT stock, giving a Buy rating today. Joel Beatty’s rating ...
FDA's promised guidelines on pulse oximeters unlikely to end decades of racial bias
For decades, widely used pulse oximeters have underestimated the oxygen needs of darker-skinned patients. Will the FDA's new ...
TipRanks on MSN4h
LLY, NVS, or ISRG: Which Healthcare Stock Scores Wall Street’s “Strong Buy” Rating?
The COVID-19 pandemic made the world realize the importance of investing in healthcare infrastructure and developing ...
GlobalData on MSN1d
FDA greenlights Exact Science’s newest home colorectal cancer test
Cologuard Plus is the second version of the company’s colorectal cancer screening test, with increased genetic biomarkers and ...
Guacamole Recall Update as FDA Sets Highest Risk Level
The guacamole, peppers, and vegetables voluntarily recalled by the maker have been classed as the highest risk level by the ...
BioAtla's FDA Fast-Tracked Drug Candidate Boosts Its Oncology Prospects, Speculative Buy
BioAtla faces a tight cash runway until Q3 2025, raising concerns about dilution and short-term stock headwinds. Find out why ...
studyfinds12d
Alzheimer’s drug breakthrough or breakdown? Investigation exposes red flags in FDA approval of donanemab
A startling investigation has revealed a troubling story behind donanemab's approval -- one of questionable data, potential ...
Buy Rating on Scholar Rock Holding: Promising Phase 3 Results and Strategic FDA/EMA Submissions Drive Positive Outlook
H.C. Wainwright analyst Andres Y. Maldonado reiterated a Buy rating on Scholar Rock Holding (SRRK – Research Report) today and set a ...
Pfizer: A 6% Yielding Ultra SWAN Bargain With Upside Potential
Pfizer (PFE) stock may present opportunities for patient investors. Read how this biotech giant may deliver long-term ...
The Washington Post12d
FDA approves a novel drug for schizophrenia, a potential ‘game changer’
The drug was not without its own side effects ... Still, she said, the evidence is based on clinical rating tools, and it can be hard to know how a score on such a test “translates into real ...
Critical Flaws: New Alzheimer’s Drug Could Actually Be a Safety Risk
An investigation has uncovered alarming issues including increased mortality rates, absent safety records, dubious efficacy, ...
MedCity News12d
FDA Approval of Bristol Myers Drug Makes It the First Novel Schizophrenia Med in Decades
FDA approval of Cobenfy was based on the results ... patients using the Positive and Negative Syndrome Scale (PANSS), a rating scale that measures symptom severity in psychotic disorders such ...